Donald P. Braun Purchases 25,000 Shares of Imunon, Inc. (NASDAQ:IMNN) Stock

Imunon, Inc. (NASDAQ:IMNN) Director Donald P. Braun acquired 25,000 shares of the business’s stock in a transaction on Tuesday, August 20th. The shares were bought at an average cost of $1.18 per share, with a total value of $29,500.00. Following the completion of the acquisition, the director now owns 25,597 shares in the company, valued at approximately $30,204.46. This represents a 4,187.60 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Imunon Trading Down 2.5 %

Shares of NASDAQ IMNN traded down $0.02 during midday trading on Tuesday, hitting $0.91. The company’s stock had a trading volume of 230,901 shares, compared to its average volume of 184,877. The business’s 50 day moving average is $0.87 and its two-hundred day moving average is $1.02. The firm has a market cap of $13.25 million, a P/E ratio of -0.48 and a beta of 2.04. Imunon, Inc. has a 12-month low of $0.48 and a 12-month high of $3.65.

Imunon (NASDAQ:IMNN) last released its quarterly earnings data on Thursday, November 7th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.37) by $0.03. During the same quarter in the previous year, the firm earned ($0.37) earnings per share. On average, analysts predict that Imunon, Inc. will post -1.68 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the company. D. Boral Capital restated a “buy” rating and set a $29.00 price target on shares of Imunon in a report on Friday. HC Wainwright reissued a “buy” rating and issued a $12.00 target price on shares of Imunon in a research note on Thursday, December 19th.

About Imunon

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.